Jean-Christoph Ballan
President and CEO of Bristol Myers Squibb and Celgene in Japan
He worked for GlaxoSmithKline in the UK and Danone in France, and in 2012 Bristol in the US he joined Myers Squib (BMS).
U.S. Pharmaceutical BMS: Donated to Mr. Honjo’s research facility at Kyoto University: Construction fund $ 53 million
Bristol Myers Squibb (BMS):
Donate to Kyoto University:
We support the research of Professor Tasuku Honjo.
Donated a total of 5.5 billion yen (about 53 million dollars) to Kyoto University for the purpose of research support.
Cancer Immunotherapy Research Center:
Cancer Immunotherapy Research Center, which will start construction in 2021.
The donation will be used to fund the construction of the headquarters building.
The head office building will be named after the BMS company name.
Cancer immunotherapy drug “Opdivo”:
BMS has acquired the exclusive right to sell the cancer immunotherapy drug “Opdivo” developed by Mr. Honjo in regions other than Japan, South Korea and Taiwan.
Opdivo became a large product as soon as it was released in Japan and the United States in 2014.
In 2019, BMS sales will reach 7.2 billion dollars (about 750 billion yen).
This donation:
It supports the research of Mr. Honjo, a longtime partner.
We asked Jean-Christoph Ballan, President and CEO of BMS Japan, about his goals.
Nikkei Business
https://business.nikkei.com/atcl/gen/19/00110/012500069/
To support cancer research in Japan: Donated his 5.5 billion yen to Kyoto University
January 26, 2021
Bristol Myers Squibb:
Today, we announced that we will donate a total of 5.5 billion yen (about 53 million US dollars) to Kyoto University to fund the construction of the Head Office of the Cancer Immunotherapy Research Center.
This donation:
His work for the purpose of “research support of the Cancer Immunotherapy Research Center, Graduate School of Medicine, Kyoto University”.
Bristol Myers Squibb Co., Ltd. will contribute the donation.
Bristol Myers Squibb Building:
Construction is scheduled to begin in 2021.
Japan’s first research institute specializing in cancer immunotherapy research.
He will work on the scientific development of his cancer immunotherapy for the next generation of cancer treatment.
It plays a role as a hub where domestic and foreign researchers gather.
Tasuku Honjo Center Director:
He was awarded the Nobel Prize in Physiology or Medicine in 2018 for his discovery of PD-1.
PD-1 is a protein that suppresses immune function, which was discovered in 1992, and this discovery later led to new cancer treatments.
Tadao Ando Architectural Institute participated in the basic design.
Jean-Christoph Ballan President:
This donation shows his strong aspiration for “the mission to develop and provide innovative cancer therapeutic agents” of his BMS, a pioneer of cancer immunotherapy.
https://www.bms.com/assets/bms/japan/pressrelease/20210126.pdf